Citations

Clear

83 citation(s) found for "Shen, Win".

Association between state-level syncope driving policies and motor vehicle crash rates in the United States
Dreher, Luke , Mishra, Nandini, Shen, Win-Kuang, Sorajja, Dan , Mishra, Nandini, Schleifer, J. William

Mayo Clinic

Traffic Injury Prevention | September 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-8

10.1080/15389588.2026.2724441 | PMID 42715491 Get It

Catheter Ablation for Atrial Fibrillation in Cardiac Amyloidosis: A Systematic Review and Meta‐Analysis
Sripusanapan, Adivitch , Deepan, Natee , Pongsukvechkul, Bheem , Kittiwongsopon, Suphatcha, Sorajja, Dan , Shen, Win‐Kuang , Chokesuwattanaskul, Ronpichai , Tan, Min Choon , Rattanawong, Pattara , Sorajja, Dan , Chokesuwattanaskul, Ronpichai , Rattanawong, Pattara , Prasitlumkum, Narut

Mayo Clinic

Journal of Arrhythmia | August 11, 2026 | Volume: 42 | Issue: 4 | Pages: No page available

10.1002/joa3.70441 | PMID 42583105 Get It

ABSTRACT Background Atrial fibrillation (AF) is prevalent in cardiac amyloidosis (CA) and is associated with adverse clinical outcomes. Catheter ablation is increasingly used for rhythm control in this population, yet its clinical outcomes remain uncertain. We performed a systematic review and meta‐analysis to evaluate arrhythmia recurrence and clinical outcomes following catheter ablation compared with medical therapy in patients with CA. Methods We systematically searched MEDLINE, Embase, and Scopus from inception through December 2025 for studies evaluating catheter ablation of atrial arrhythmias in CA. Cohort studies reporting arrhythmia recurrence and/or clinical outcomes were included. The primary outcome was freedom from atrial arrhythmia (AA) following ablation. Secondary outcomes included all‐cause mortality, heart failure hospitalization, and stroke. Random‐effects models were used to pool event rates and odds ratios (ORs). Results Thirteen observational studies comprising 797 patients with CA and AF were included. The pooled rate of freedom from AA following catheter ablation was approximately 50% (95% CI 37%–63%; I 2 = 71.7%). The all‐cause mortality analysis included 4 observational studies comprising 616 patients. Catheter ablation was associated with lower odds of all‐cause mortality (OR 0.26, 95% CI 0.11–0.60; I 2 = 18.4%); however, this association should be interpreted with caution given the retrospective design and risk of bias. No statistically significant differences were observed for heart failure hospitalization or stroke. Conclusions In patients with CA, catheter ablation was associated with modest arrhythmia‐free survival and lower odds of all‐cause mortality. However, all contributing studies were observational cohorts. Randomized studies are needed to confirm these findings.
Physiology-guided cardioneuroablation for vagally mediated syncope and functional bradyarrhythmias
Kowlgi, Gurukripa N. , Pachón-M, José Carlos , Prasitlumkum, Narut , Gulati, Arvind, Yoo, Jeanwoo , Karlen, Kallie, Tan, Nicholas Y. , Sugrue, Alan , Killu, Ammar M. , Deshmukh, Abhishek , Munoz, Freddy Del‐Carpio , Siontis, Konstantinos C. , Madhavan, Malini , Friedman, Paul A. , Pachon-Mateos, Enrique, Pachon, Carlos, Acosta, Juan , Cha, Yong‐Mei , Shen, Win‐Kuang , Kowlgi, Narayan G , Prasitlumkum, Narut , Pachon, Jose C , Gulati, Arvind, Kapa, Suraj , DeSimone, Christopher V. , Noseworthy, Peter A. , Mateos, Enrique I. Pachon-, Pachon, Carlos Thiene C., Asirvatham, Samuel J.

Mayo Clinic

No container title available | August 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.03.26359633 Get It

Abstract Background Vagally mediated syncope and functional bradyarrhythmias can cause recurrent symptoms, injury and a need for permanent pacing, yet standard therapies do not address the underlying autonomic reflex. Cardioneuroablation (CNA) targets this mechanism, but adoption has been limited by uncertainty about patient selection, procedural endpoints and durable outcomes. Methods We studied 95 consecutive patients with vagally mediated syncope (n=78) or functional bradyarrhythmia (n=17) who underwent CNA at a single center by a single lead operator under a uniform, prospectively maintained protocol. Extracardiac vagal stimulation (ECVS) was performed before and after ablation to confirm vagally mediated sinus or atrioventricular (AV) nodal responses and to verify their attenuation. Outcomes through 1 year included clinical recurrence, quality of life, pacing burden and pacemaker extraction. Results Before ablation, ECVS provoked sinus pauses in 95.8% of patients and AV block in 91.6%; after ablation, sinus pauses were abolished in every patient and residual AV block was present in 4.2%. One-year freedom from recurrent syncope and from bradyarrhythmia-related events was 93.8% and 94.1%. Syncope burden fell from a median of 2.7 episodes per year to none, and disease-specific quality of life improved substantially (P<0.001). Among patients with pre-existing devices, atrial pacing burden fell from a median of 22% to 0%. There were no strokes, deaths or myocardial infarctions. Conclusions In this single-center cohort, physiology-guided CNA was associated with durable symptom control, improved quality of life and reduced pacing across vagally mediated bradyarrhythmia syndromes. Multicenter controlled studies are needed to confirm these findings.
Lipoprotein(a) and Risk of Treated Ventricular Arrhythmias in Heart Failure
Ibrahim, Ramzi, Dreher, Luke, Habib, E., Pham, Hoang Nhat, Ibrahim, Sammudeen , Bhakta, Mayurkumar, Sorajja, Dan , Shen, Win-Kuang, Scott, Luis R., Ayoub, C A, Arsanjani, R A, Masry, Hicham Z. El, Masry, Hicham El , Nabi, Hussein Abdul , Farina, Juan María, Tan, Min Choon , Noureldine, Hussein A , El Masry, Hicham Z, El Masry, Hicham , Ibrahim, Ramzi , Dreher, Luke , Farina, Juan M. , Pham, Hoang Nhat , Bhakta, Mayurkumar D. , Lee, Kwan , Scott, Luis R. , Arsanjani, Reza

Mayo Clinic

JAMA Network Open | May 26, 2026 | Volume: 9 | Issue: 5 | Pages: e2614674

10.1001/jamanetworkopen.2026.14674 | PMID 42189543 Get It

This cross-sectional study investigates the association between lipoprotein(a) levels and risk of ventricular arrhythmias among patients with heart failure with reduced ejection fraction receiving implantable cardioverter-defibrillator therapy.
Post-Catheter Ablation Long-Term Antithrombotic Strategies in Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials
Rodriguez-Riascos, Juan F., Navale, Dravid, Somappa, Aakash , Mendizabal, Ricardo Estrada, Scott, Luis R., Shen, Win-Kuang, Srivathsan, Komandoor , Estrada-Mendizábal, Ricardo J. , Rodriguez, Juan F. , Rodriguez-Riascos, Juan F , Estrada-Mendizabal, Ricardo J , Scott, Luis R , Shen, Win-Kuang , Srivathsan, Komandoor , Scott, Luis R.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | April 3, 2026 | Volume: 19 | Issue: 4 | Pages: No page available

10.1161/circep.125.014692 | PMID 41930400 Get It

BACKGROUND: Catheter ablation for atrial fibrillation is a widely used rhythm-control strategy, yet its role in reducing thromboembolic risk and enabling oral anticoagulation (OAC) discontinuation remains uncertain. This meta-analysis aims to comprehensively synthesize and evaluate randomized controlled trial evidence supporting long-term antithrombotic strategies in patients with atrial fibrillation undergoing catheter ablation. METHODS: A systematic literature search was performed in MEDLINE/PubMed, Embase, and the Cochrane Central Register of Controlled Trials to identify randomized controlled trials evaluating antithrombotic strategies after catheter ablation for atrial fibrillation. The primary outcome was ischemic stroke. A frequentist network meta-analysis comparing reported treatment arms, along with a pooled incidence meta-analysis for outcomes of interest, was conducted. RESULTS: Four randomized controlled trials, including 3924 patients, met the inclusion criteria. Three trials compared long-term OAC continuation versus OAC discontinuation, and 1 compared OAC continuation with left atrial appendage occlusion after catheter ablation. No significant differences in stroke incidence were observed when comparing OAC or left atrial appendage occlusion with no antithrombotic therapy (incidence rate ratio, 0.90 [95% CI, 0.02–33.85]; P =0.95; incidence rate ratio, 0.79 [95% CI, 0.00–241.01]; P =0.94, respectively). Among patients who discontinued antithrombotic therapy without undergoing left atrial appendage occlusion (n=1161), with 2864 cumulative person-years of follow-up, the pooled incidence of stroke was 0.23 events per 100 person-years (95% CI, 0.02–2.43; I 2 =0%). CONCLUSIONS: This analysis reinforces that, across randomized data, the incidence of thromboembolic events in patients who discontinued OAC after successful ablation remained low. However, the evaluation of net clinical benefit is limited by the low number of events across all treatment arms, underscoring the need for larger studies with prolonged follow-up to further validate the safety of this strategy, particularly in higher-risk populations.
Brugada syndrome risk scores: what we've learned and what's next
Rattanawong, Pattara, Shen, Win-Kuang, Rattanawong, Pattara

Mayo Clinic

Frontiers in Cardiovascular Medicine | January 30, 2026 | Volume: 12 | Issue: No issue available | Pages: No page available

10.3389/fcvm.2025.1715146 | PMID 41696545 Get It

Brugada Syndrome (BrS) is a rare but clinically significant inherited arrhythmia disorder characterized by a type 1 ECG pattern and an increased risk of sudden cardiac death (SCD). Since its first description in 1992, BrS has been the subject of intensive investigation, yet risk stratification remains one of its greatest challenges. While survivors of cardiac arrest and patients with documented ventricular fibrillation (VF) are clear candidates for implantable cardioverter-defibrillators (ICDs), predicting risk in asymptomatic or intermediate-risk individuals is less straightforward. Over the past two decades, multiple risk scores have been developed—including the Sieira, Shanghai, BRUGADA-RISK, and PAT—each integrating combinations of clinical, ECG, electrophysiological study (EPS), and genetic data. Performance metrics vary, with C-statistics ranging from 0.70 to 0.82 in derivation cohorts, but external validation has often been limited. Importantly, current ESC and AHA/ACC guidelines only endorse syncope and EPS inducibility as validated predictors, reflecting the cautious stance of expert panels in the face of heterogeneous data. Nonetheless, the emergence of structured risk models has improved our ability to stratify intermediate-risk patients and stimulated further innovation. Looking ahead, opportunities lie in integrating artificial intelligence applied to raw ECG waveforms, wearable technology for dynamic monitoring, advanced cardiac imaging biomarkers, and polygenic risk scores. Multinational collaboration and federated learning will be essential to overcome statistical fragility and ensure global applicability. Ultimately, BrS risk scores should be considered decision-support tools that enrich but do not replace clinical judgment. Shared decision-making remains central, particularly in asymptomatic patients where ICD implantation is not a clear-cut choice.
Safety, Efficacy, and Mid-Term Outcomes of Pulsed Field Ablation for Cavotricuspid Isthmus–Dependent Flutter: Real-World Data From a Major Health System Registry
Rodriguez, Juan F. , Vemulapalli, Hema Srikanth , Prajapati, Poojan , Muthu, Padmapriya , Kim, James Y. , Sorajja, Dan , Shen, Win‐Kuang , Masry, Hicham El , Valverde, Arturo M. , Munger, Thomas M. , Rodriguez-Riascos, Juan F , Vemulapalli, Hema S , El Masry, Hicham , Sardana, Mayank , Valverde, Arturo M , Srivathsan, Komandoor , Muthu, Padmapriya , Srivathsan, Komandoor , Kim, James

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | December 2, 2025 | Volume: 18 | Issue: 12 | Pages: No page available

10.1161/circep.125.014276 | PMID 41328574 Get It

BACKGROUND: Cavotricuspid isthmus (CTI) ablation is frequently performed either as a standalone procedure or in combination with pulmonary vein isolation. With the rapid adoption of pulsed field ablation for atrial fibrillation, it is essential to delineate the utility of this modality in treating CTI-dependent atrial flutter (AFL). This study aims to evaluate the procedural and clinical outcomes of CTI ablation using pulsed field energy. METHODS: We conducted a retrospective analysis of consecutive patients who underwent pulsed field ablation for CTI-dependent AFL between January 2024 and March 2025. The primary end points were acute procedural success, periprocedural complications, and CTI-dependent AFL recurrence during follow-up. RESULTS: A total of 132 patients underwent CTI nonthermal ablation. The median age was 69.5 years, and 27.3% were female. The Farawave catheter was used in 93.9% of cases, PulseSelect in 4.5%, and Sphere-9 in 1.5%. Acute block was achieved in 99.2% of patients, although 8 required adjunctive radiofrequency ablation to complete the line. Periprocedural complications included transient ST-segment elevation in 2 patients and transient conduction disturbances in 3. During a median follow-up of 114 days (n=131), 5 patients (3.8%) experienced recurrence of typical AFL. The 6-month typical AFL-free survival estimate was 93.6%. CONCLUSIONS: Pulsed field ablation appears to be a feasible and effective strategy for CTI-dependent AFL. However, anatomic variability may limit its universal applicability with current catheter designs. Although acute procedural success is high, the long-term durability of the CTI block and its comparative efficacy versus conventional thermal ablation remain areas requiring further investigation.
Abstract 4371556: Reassessing the Blanking Period: Early Recurrence as a Predictor of Late Atrial Fibrillation Recurrence After Pulsed Field Ablation
Rodriguez-Riascos, Juan, Kim, James , Sripusanapan, Adivitch , Prajapati, Poojan , Fatunde, Olubadewa A. , Sorajja, Dan , Shen, Win K., Rodriguez, Juan F. , Vemulapalli, Hema Srikanth , Masry, Hicham El , Srivathsan, Komandoor

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4371556 Get It

Background: A blanking period allowing for atrial fibrillation (AF) recurrence after pulmonary vein isolation (PVI) has historically been standardized to 90 days. With the recent introduction of pulsed field ablation (PFA) for PVI and emerging in vitro data suggesting a shorter inflammatory timeframe, it remains unclear whether recurrences during this 90-days period reflect incomplete procedural success or merely transient inflammatory changes. Research Question: In patients undergoing PVI with PFA, do early AF recurrences at 30, 60, and 90 days predict late AF recurrences beyond the standardized 90-day blanking period? Methods: Patients undergoing PFA for AF were retrospectively included. Procedures were performed under general anesthesia, and high-density (HD) mapping, with PVI and additional ablation lines applied at the operator’s discretion. PFA catheters included Farawave, PulseSelect, and Sphere-9. AF recurrences were defined as documented episodes on 12-lead ECG or cardiac monitoring devices, confirmed by interpretation from an experienced cardiologist. Survival analyses were conducted based on the occurrence of early recurrences at 30, 60, and 90 days post-ablation. Kaplan-Meier curves and hazard ratios were reported. This study was approved by our institutional review board. Results: To the best of our knowledge, this is the largest real-world study reporting outcomes of PFA for AF in the United States. A total of 1,214 patients were included in the analysis. Mean age was 66.4 years; 31.9% were female, and 22.4% underwent redo PVI. Six-month AF recurrence-free survival was 79% (95% CI, 75–83%) for the overall cohort. Patients experiencing early recurrence at 30, 60, and 90 days had a significantly higher risk of AF recurrence beyond the standardized 90-day blanking period (HR 4.0, 95% CI 2.7–5.9, P < 0.01; HR 5.0, 95% CI 3.6–7.1, P < 0.01; and HR 6.9, 95% CI 4.9–9.6, P < 0.01, respectively). Conclusion: Early recurrences at 30, 60, and 90 days post-ablation are strongly associated with atrial fibrillation recurrence beyond the 90-day blanking period. These findings challenge the traditional concept of blanking period after PFA and suggest that early recurrence may indicate incomplete procedural success rather than transient inflammation.
Abstract 4364607: Clinical Impact of Proton Beam Radiation on Pacemakers and ICDs: Insights from the RADIATE-CIED Registry
Suppah, Mustafa , Mousa, Hana, Lee, Justin Z. , Schwartz, Linda, Harrington, Daniel P. , Shen, Win K., Cha, Yong‐Mei , Sorajja, Dan , Schwartz, Linda, Kusumoto, Fred

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4364607 Get It

Background: Patients with cardiac implantable electronic devices (CIEDs) undergoing radiation therapy face potential risks of device malfunction. Proton beam therapy (PBT), with its reduced neutron scatter, has emerged as a potentially safer alternative, yet real-world safety data remain scarce. Methods: We conducted a retrospective cohort study of 100 patients with CIEDs (76 pacemakers, 24 ICDs) who underwent PBT from 2016 to 2023 at a quaternary center. Baseline and serial device interrogations were performed before, during, and after treatment to assess lead impedance, capture thresholds, battery function, and arrhythmic events. Patients were stratified by pacemaker dependence and monitored accordingly. Primary outcomes included device malfunction and new-onset arrhythmias during treatment. Secondary outcomes included device parameter changes, one-year arrhythmia incidence, and cardiac-related hospitalizations. Results: No treatment-related deaths or major device failures occurred. Device malfunction was rare (2 pacemaker patients, 2.6%), with no malfunctions in ICD recipients. Transient, non-clinically significant changes in lead impedance and capture thresholds were observed. Arrhythmias during treatment occurred in 26% of pacemaker and 25% of ICD patients, but only 4% developed new arrhythmias. At one year, device-related complications and cardiac outcomes remained comparable across groups. Independent predictors of arrhythmias during treatment included a higher radiation dose per fraction (OR 1.45; p=0.001), a longer treatment duration (OR 1.12; p=0.04), and a higher number of fractions (OR 1.20; p=0.01). Conclusion: Proton beam therapy appears safe in patients with CIEDs, with a low incidence of clinically significant device malfunctions or arrhythmias. These findings support the integration of PBT into routine practice for this population and underscore the importance of structured monitoring protocols and prospective guideline refinement.
Abstract 4361592: State-Level Syncope Driving Restrictions and Crash Risk in Older Adults: A National Comparative Analysis
Dreher, Luke , Mishra, Nandini, Shen, Win K., Sorajja, Dan , Mishra, Nandini

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4361592 Get It

Background: Syncope is a leading cause of transient loss of consciousness, especially in older adults. Post-syncopal driving restrictions are widely recommended, but the required duration varies by state. The impact of these policies on motor vehicle crash outcomes remains unclear. Methods: We conducted a cross-sectional analysis of 45 U.S. states, comparing crash and fatality data between states requiring < 6 months vs. ≥ 6 months of driving restriction following a syncopal episode. Data were obtained from Fatality Analysis Reporting System, National Highway Traffic Safety Administration, state Department of Motor Vehicles, and medical boards. Crash rates were normalized by licensed drivers and population. Statistical comparisons were made using Welch’s t-tests. Results: States with ≥ 6-month restrictions had significantly lower crash rates among older drivers (0.0171 vs. 0.0256, p = 0.0076). Relative crash ratios comparing older to younger drivers were also lower (0.220 vs. 0.306, p = 0.067). Overall crash rates trended lower in states with ≥ 6-month restrictions in both per licensed driver ( p = 0.054) and per population ( p = 0.099). No significant differences were observed in fatality rates. Conclusions: Longer post-syncope driving restriction durations (≥ 6 months) are associated with reduced crash risk among older drivers and a narrowing of age-related disparities in crash rates. These findings suggest potential public health value in adopting more uniform, evidence-based restriction policies following syncopal events for older drivers.